Our media section contains our recent and archived corporate videos, interviews and presentations

Categories:

30 Sep 25Investor Meet Company Presentation Watch
29 Sep 25VOX Markets Interims Interview Watch
29 Sep 25Proactive Investors Interims Interview Watch
25 Sep 25VOX Markets POLB 001 Phase 2a Trial Watch
25 Sep 25Proactive Investors POLB 001 Phase 2a Trial Watch
12 Sep 25Base to Base biotech podcast 26 – Stand Up To Cancer Day Listen
11 Sep 25Immunotherapy and the Future of Oncology – Breakthroughs, Barriers, and the Road Ahead Watch
11 Sep 25Jeremy Skillington summarises POLB 001 benefits for cancer immunotherapy Watch
10 Sep 25Poolbeg Pharma on a a new cancer immunity Listen
10 Sep 25Poolbeg CEO On The Biotech’s Big Bet On Small Molecules Listen
5 Aug 25Poolbeg CEO On The Biotech’s Big Bet On Small Molecules Listen
30 Jul 25Poolbeg Pharma on a a new cancer immunity Listen
3 Jul 25Jeremy Skillington interview with Total Market Solutions Watch
30 Jun 25Poolbeg Pharma (POLB) Shares Spotlight Exhibition Watch
24 Jun 25POOLBEG PHARMA PLC – Company Presentation Watch
29 May 25POOLBEG PHARMA PLC – Investor Presentation Watch
28 May 25Q&A with Poolbeg Pharma CEO, Jeremy Skillington Watch
27 May 25Poolbeg Pharma granted FDA Orphan Drug Designation for treatment in cancer immunotherapy Watch
8 Apr 25Master Investor Show 2025 – Jeremy Skillington – Poolbeg Pharma Watch
3 Apr 25Poolbeg Pharma at Master Investor Show 2025 Watch
26 Feb 25Company Presentation February 2025 Watch
31 Oct 24Principal Scientist Liam Tremble on GLP-1 Receptor Agonists Watch
18 Sep 24Jeremy Skillington on Poolbeg’s Rare Disease Strategy & New Developments Watch
18 Sep 24VOX Interview with CEO, Jeremy Skillington from Poolbeg Pharma Watch
22 Aug 24Non-Executive Director Professor Luke O’Niell on POLB 001 & AI Watch
24 Jul 24The Newry Lawyer and the Irish Unicorn Listen
25 Jun 24PiWorld Investor Presentation Watch
30 May 24How AI is revolutionising drug research Listen
28 May 24Immense promise for cashed up Poolbeg Pharma Watch
20 May 24Poolbeg Pharma – Well Positioned for Success with CEO Jeremy Skillington Watch
1 May 24Poolbeg Pharma Plc – Company Update April 2024 Watch
30 Apr 24Poolbeg Pharma FY Results:“ we’ve selected our development processes to be very cost efficient” Watch
30 Apr 24Poolbeg Pharma and Silk Road Therapeutics announce strategic collaboration on novel orphan drug Watch
24 Apr 24Jeremy Skillington, PhD, CEO, Poolbeg Pharma, ‘It’s like a checkbox of everything you wanted’, episode 64 Listen
13 Mar 24Q&A with Poolbeg CEO Jeremy Skillington & Chief Business Office David Allmond Watch
4 Mar 24Poolbeg Pharma POLB – CEO Jeremy Skillington talks to Alan Green Watch
12 Feb 24Poolbeg Pharma says research confirms $10B plus opportunity for POLB 001 in cancer immunotherapies Watch
8 Feb 24Poolbeg Pharma’s Allmond hopes to replicate Amryt success Watch
7 Feb 24Poolbeg Pharma’s new VP of Clinical Operations Laura Maher aims to help progress development assets Watch
23 Jan 24Poolbeg Pharma CLO reveals what he’s “looking to get his teeth into” in 2024 Watch
18 Jan 24Poolbeg Pharma Plc – Company Update January 2024 Watch
18 Jan 24Poolbeg Pharma announces more “very positive” efficacy data for POLB 001 Watch
17 Jan 24Q&A: Poolbeg Pharma on target for $1bn cancer opportunity Open
31 Dec 23Poolbeg Pharma year in review: deepening strength Watch
31 Dec 23Year in Review 2023 Watch
11 Nov 23POOLBEG PHARMA PLC – Company Update: November 2023 Watch
7 Nov 23POLB 001 Oncology Programme Update: November 2023 Watch
17 Oct 23Poolbeg Pharma unveils new collaboration agreement Watch
17 Oct 23Poolbeg Pharma Partners with a Nasdaq-Listed Biopharma Company on its Oral Delivery Platform Watch
13 Oct 23AI & Lab Automation: What are the key benefits and latest innovations to be aware of? Watch
25 Sep 23Master Investor Sector Focus: Healthcare Watch
20 Sep 23AI Unleashed: Experts from Poolbeg Pharma & CytoReason Watch
13 Sep 23Jeremy Skillington of Poolbeg Pharma: 2023 saw significant progress in advancing our pipeline Listen
13 Sep 23Poolbeg Pharma “moving forward rapidly” with POLB001 Watch
4 Sep 23Poolbeg Pharma A.I. Unlocking the power of unique human challenge trial data Watch
30 Aug 23Scientific Advisor at Poolbeg Pharma: Paula Maquire Watch
8 Aug 23CEO Jeremy Skillington talks to Alan Green Watch
8 Aug 23Poolbeg Pharma: Using AI to prepare for the next pandemic Listen
21 Jul 23VP of Regulatory Affairs of Poolbeg Pharma: Bruno Speder Watch
10 Jul 23Poolbeg Pharma at the forefront of AI drug discovery as it approaches IPO anniversary Watch
29 Jun 23Poolbeg Pharma and CytoReason identify “very exciting influenza targets” Watch
29 Jun 23Q&A: Poolbeg Pharma CEO Jeremy Skillington on its groundbreaking AI collaboration Listen
26 May 23Poolbeg Pharma’s new NED looking at “new opportunities” for the business Watch
17 May 23BioCentury Podcast – Fundraising struggles, an LSE surprise and Ireland’s burgeoning biotech ecosystem Listen
31 Mar 23POOLBEG PHARMA PLC – Full Year Results Watch
30 Mar 23Poolbeg Pharma “in a very healthy cash position” after first full year of operations Watch
30 Mar 23Poolbeg’s Jeremy Skillington on a groundbreaking year Listen
3 Mar 23POOLBEG PHARMA PLC – Company Presentation (Investor Meet) Watch
2 Mar 23Poolbeg Pharma “couldn’t be happier” with POLB 001 human challenge trial data Watch
2 Mar 23Poolbeg’s Jeremy Skillington: “the results are as good as we hoped for” Listen
1 Mar 23Poolbeg CEO Jeremy Skillington gave a POLB 001 update & explained how they use AI to speed discovery Watch
27 Feb 23Poolbeg Pharma & OneThree Biotech: Collaboration and Themes in AI Watch
24 Feb 23Poolbeg Pharma “really open” to different types of deal for POLB 001 Watch
20 Feb 23Poolbeg Pharma Investment Case Watch
11 Feb 23Elaine Sullivan on International Day of Women & Girls in Science Watch
20 Jan 23POLB 001, a potential companion therapy for CAR T Cell Therapy Watch
16 Jan 23POOLBEG PHARMA PLC – Investor Presentation Watch
16 Jan 23Poolbeg Pharma announces expansion of POLB 001 into oncology Watch
16 Jan 23Vox Markets Podcast: Jeremy Skillington, CEO Poolbeg Pharma Listen
9 Jan 23Poolbeg Pharma upbeat on preliminary influenza drug results Watch
9 Jan 23Jeremy Skillington of Poolbeg Pharma: Early data read out for POLB 001 indicates a successful LPS human challenge trial Listen
3 Jan 23Year in Review 2022 Watch
21 Dec 22Poolbeg Pharma identifies new RSV drug candidates Watch
21 Dec 22Jeremy Skillington of Poolbeg Pharma: First time RSV drug candidates have been identified using AI Listen
21 Dec 22Poolbeg Pharma year in review: fighting disease with AI Watch
15 Dec 22POOLBEG PHARMA PLC – Investor Presentation Watch
14 Dec 22Jeremy Skillington of Poolbeg Pharma: licence acquired to use innovative oral delivery technology to address large, fast-growing opportunity Listen
14 Dec 22Poolbeg Pharma makes “interesting addition to existing collaboration” Watch
13 Dec 22Poolbeg Pharma has its sights on exchange listing Watch
13 Dec 22POLB 001 LPS human challenge clinical trial successfully completed Watch
12 Dec 22Jeremy Skillington of Poolbeg Pharma: POLB 001 LPS human challenge clinical trial successfully completed Listen
12 Dec 22Poolbeg Pharma receives initial results from human challenge clinical study Watch
8 Dec 22LSX Poolbeg Showcase Presentation Watch
30 Nov 22Capital Markets Day Open
21 Nov 22Introduction to David English, VP of Business Development Watch
18 Nov 22Poolbeg Pharma & OneThree Biotech on AI programme for RSV drug targets Watch
15 Nov 22Jeremy Skillington of Poolbeg Pharma discusses their consortium award of €2.3m in non-dilutive grant funding Listen
15 Nov 22Poolbeg Pharma wins first non-dilutive grant funding Watch
8 Nov 22Jeremy Skillington of Poolbeg: First time AI has been used to identify multiple disease targets in RSV Listen
8 Nov 22Poolbeg Pharma makes virus “breakthrough” using AI drug discovery technology Watch
8 Nov 22Poolbeg Pharma presents at the London South East Investor Webinar Watch
6 Oct 22Poolbeg Pharma presents at the Proactive One2One Investor Forum – October 6th 2022 Watch
5 Oct 22StockBox Premiere with Oxford Cannabinoid, Poolbeg Pharma & Destiny Pharma Watch
19 Sep 22Cash flush Poolbeg Pharma says investors should watch out for a number of near-term value catalysts Watch
7 Sep 222022 Interim Results: Financial & Corporate Highlight Interview with BRR Media Watch
6 Sep 22Poolbeg interim results highlight strong cash position and significant advancement of porfolio. Open
6 Sep 22Poolbeg Pharma advancing portfolio of products and platforms which is ‘driving value’ Watch
6 Sep 22POOLBEG PHARMA PLC – Interim Results Watch
28 Jul 22A landmark year for Poolbeg Pharma #POLB – Alan Green talks to CEO Jeremy Skillington Watch
20 Jul 22POLB 001 achieves regulatory approval to commence human challenge clinical trial Listen
20 Jul 22Poolbeg Pharma achieves major milestone with POLB 001 human challenge clinical trial ready to start Watch
20 Jul 22POLB 001 Human Challenge Trial Ready to Commence Watch
14 Jul 22Proactive One2One Investor Presentation Watch
27 Jun 22Poolbeg Pharma is advancing an AI venture to help combat RSV Watch
27 Jun 22AI partner has completed build & optimisation of RSV human challenge data Listen
23 Jun 22OTC Virtual Investor Conference, Life Science Presentation Watch
9 Jun 22Poolbeg Pharma (POLB) – Sharesoc Webinar Watch
6 Jun 22Poolbeg Pharma Presentation at UK Investor Show Watch
30 May 22Poolbeg Pharma announce two US patents Watch
15 May 22LSX World Congress Showcase Poolbeg Pharma Watch
12 May 22Alan Bell discusses POLB 001 Update & GMP Manufacturing Contract Watch
28 Apr 22Poolbeg Pharma delighted with outcome of in-Specie offer Watch
27 Apr 22Poolbeg Pharma PLC presenting at the One2One Forum 26th April 2022 Watch
27 Apr 22Cathal Friel on Results of the proposal to purchase shares from Distribution in Specie shareholders Watch
27 Apr 22Cathal Friel of Poolbeg Pharma discusses results of the proposal to purchase shares from distribution in specie shareholders Listen
15 Apr 22Poolbeg Pharma delighted with patent for flu treatment candidate Watch
11 Apr 22Cathal Friel of Poolbeg Pharma: Specie share purchase should increase liquidity & maximise shareholder value Listen
11 Apr 22Poolbeg Pharma PLC proposed share transfer is validation that shares are “cheap at this price” Watch
1 Apr 22Poolbeg Pharma POLB 001 Clinical Development – Clinical Trial Agreement Signed Watch
31 Mar 22CEO Jeremy Skillington on Poolbeg Pharma’s OTCQB Listing Watch
31 Mar 22Jeremy Skillington of Poolbeg Pharma discusses the clinical trial agreement for POLB 001 human challenge study Listen
25 Mar 22Jeremy Skillington & Luke O’Neill on Poolbeg’s AI Programme Watch
24 Mar 22Jeremy Skillington of Poolbeg Pharma discusses their deal with CytoReason, a leading AI company Listen
24 Mar 22Poolbeg Pharma plan to ‘unlock’ the influenza disease with CytoReason after signing AI deal Watch
4 Mar 22POOLBEG PHARMA PLC – Investor Presentation Watch
3 Mar 22Poolbeg Pharma Results to 31 December 2021 – Chairman & CEO Watch
3 Mar 22Cathal Friel & Jeremy Skillington of Poolbeg Pharma discuss the significant progress since IPO & growing pipeline Listen
3 Mar 22Poolbeg Pharma making ‘excellent progress post IPO as momentum builds’ Watch
1 Mar 22Brad Pryde on OneThree AI deal with Poolbeg Pharma Watch
28 Feb 22Liam Tremble – Project Manager, R&D Operations on OneThree AI Deal Watch
24 Feb 22Poolbeg Pharma’s Jeremy Skillington presents new deal with AI in developing new RSV drugs Watch
24 Feb 22Jeremy Skillington of Poolbeg Pharma discusses the Artificial Intelligence deal with OneThree Biotech Listen
9 Feb 22Poolbeg Pharma CEO Jeremy Skillington tells London South East 2022 is all about execution Watch
20 Jan 22Presenting at the proactive One2One Virtual Forum Watch
17 Jan 22Poolbeg Pharma in-licencing exciting programmes ready for big pharma Watch
17 Jan 22Poolbeg Pharma present deal with the University of Warwick for respiratory virus infections Watch
17 Jan 22Growing a Capital Light Company CEO Jeremy Skillington talks to Alan Green Watch
5 Jan 22Poolbeg Pharma Progress in 2021 – BRR Media Watch
9 Dec 21Proactive One2One Virtual Forum Watch
1 Dec 21Introduction to Dr Elaine Sullivan – Scientific Advisor Board Watch
22 Nov 21Poolbeg Pharma presents at MelloMonday Watch
19 Nov 21POLB 001 Update Watch
18 Nov 21Poolbeg Pharma makes progress with POLB 001, its lead asset for the treatment of severe influenza Watch
18 Nov 21Cathal Friel & Jeremy Skillington of Poolbeg Pharma discuss progress on their lead asset POLB 001 Listen
9 Nov 21Poolbeg Pharma #POLB – Exec Chairman Cathal Friel & CEO Jeremy Skillington talk to Alan Green Watch
9 Nov 21Poolbeg Pharma’s access to vast array of human challenge data & samples Watch
21 Oct 21Jeremy Skillington Poolbeg Pharma Overview Watch
20 Oct 21Open Orphan pharma spin-out Poolbeg Pharma present at London South East’s October live event Watch
14 Oct 21Poolbeg Pharma makes moves to protect its virus diagnostic platform by filing for a patent Watch
12 Oct 21Poolbeg Pharma (POLB) – Jeremy Skillington, CEO & Cathal Friel, Chairman Watch
11 Oct 21Poolbeg Pharma and Future Pandemic Prevention & Preparedness Watch
11 Oct 21Poolbeg Pharma partner with Eurofins Genomics for AI data analysis Watch
7 Oct 21Jeremy Skillington of Poolbeg Pharma explains their RNA sequencing partnership with a leading global biopharma services company Listen
7 Oct 21Poolbeg Pharma reveal ‘exciting step’ with AI data analysis programme with Eurofins Genomics Watch
30 Sep 21Professor Luke O’Neill thoughts on Poolbeg Pharma’s POLB 001 Watch
29 Sep 21Poolbeg One2One Questions Answered Part 1 Watch
29 Sep 21Poolbeg One2One Questions Answered Part 2 Watch
29 Sep 21One2One Questions Answered Part 1 Watch
29 Sep 21One2One Questions Answered Part 2 Watch
27 Sep 21Luke O’Neill Poolbeg Pharma Interview with BRR Media Watch
23 Sep 21Professor Luke O’Neill background and reasons for joining Poolbeg Pharma Watch
16 Sep 21Poolbeg Pharma Presenting at the Proactive One2One Virtual Forum Watch
7 Sep 21Poolbeg Pharma – inspiration for the name Watch
2 Sep 21Poolbeg Pharma Leadership Team Watch
25 Aug 21Poolbeg Pharma Investor Information Watch
16 Aug 21Poolbeg Pharma – Broad Asset Portfolio Watch
11 Aug 21Poolbeg Pharma is building a leading infectious disease company with a wide asset portfolio Watch
22 Jul 21Poolbeg Pharma plc joins London Stock Exchange Watch
20 Jul 21Poolbeg CEO Jeremy Skillington & Chairman Cathal Friel – BRR Media Watch
20 Jul 21Jeremy Skillington, CEO – Poolbeg Pharma Watch
19 Jul 21Jeremy Skillington and Proactive Investors – Poolbeg Pharma Watch
19 Jul 21Luke O’Neill on Poolbeg Pharma Watch

Poolbeg Pharma
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.